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Abstract
Bullous pemphigoid is an autoimmune blistering skin disease associated with autoantibodies against the dermal-epidermal
junction. Passive transfer of antibodies against BP180/collagen (C) XVII, a major hemidesmosomal pemphigoid antigen, into
neonatal mice results in dermal-epidermal separation upon applying gentle pressure to their skin, but not in spontaneous
skin blistering. In addition, this neonatal mouse model precludes treatment and observation of diseased animals beyond 2–
3 days. Therefore, in the present study we have developed a new disease model in mice reproducing the spontaneous
blistering and the chronic course characteristic of the human condition. Adult mice were pre-immunized with rabbit IgG
followed by injection of BP180/CXVII rabbit IgG. Mice pre-immunized against rabbit IgG and injected 6 times every second
day with the BP180/CXVII-specific antibodies (n=35) developed spontaneous sustained blistering of the skin, while mice
pre-immunized and then treated with normal rabbit IgG (n=5) did not. Blistering was associated with IgG and complement
C3 deposits at the epidermal basement membrane and recruitment of inflammatory cells, and was partly dependent on Ly-
6G-positive cells. We further used this new experimental model to investigate the therapeutic potential of luteolin, a plant
flavonoid with potent anti-inflammatory and anti-oxidative properties and good safety profile, in experimental BP. Luteolin
inhibited the Fcc-dependent respiratory burst in immune complex-stimulated granulocytes and the autoantibody-induced
dermal-epidermal separation in skin cryosections, but was not effective in suppressing the skin blistering in vivo. These
studies establish a robust animal model that will be a useful tool for dissecting the mechanisms of blister formation and will
facilitate the development of more effective therapeutic strategies for managing pemphigoid diseases.
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Introduction
Pemphigoids are autoimmune blistering disorders associated
with autoimmunity against hemidesmosomal proteins [1]. Colla-
gen XVII (CXVII) is a major autoantigen in different pemphigoid
diseases, including bullous pemphigoid (BP), pemphigoid gestatio-
nis, linear IgA disease, mucous membrane pemphigoid and lichen
planus pemphigoides [1]. BP is a prototypical organ-specific
autoimmune diseases of the skin associated with subepidermal
blisters and autoimmunity against the hemidesmosomal proteins
CXVII and BP230 at the dermal-epidermal junction (DEJ) [1,2].
While the plakin protein BP230 is an intracellular hemidesmoso-
mal component [3,4], CXVII also known as the bullous
pemphigoid antigen of 180 kDa (BP180) is a transmembrane
collagen with its N-terminus intracellularly located, its ectodomain
spanning the lamina lucida, and its C-terminus reaching the
lamina densa of the basement membrane [5,6]. The ectodomain
of BP180/CXVII consists of 15 interrupted collagenous regions
and contains major epitopes of pemphigoid autoantibodies and
autoreactive T cells within its 16
th non-collagenous (NC16A)
region [7–9]. Further antigenic determinants in pemphigoid
diseases were shown on both intra- and extracellular domains of
BP180/CXVII [10,11].
The pathogenic significance of autoantibodies against BP180/
CXVII is supported by several lines of evidence: (1) serum levels of
circulating autoantibodies against BP180/CXVII correlate with
disease activity in patients with BP [12–15]; (2) pemphigoid
autoantibodies and rabbit antibodies generated against BP180/
CXVII recruit leukocytes to the DEJ and induce dermal-
epidermal separation of human skin [16,17]; (3) rabbit antibodies
generated against BP180/CXVII induce subepidermal blistering
when injected into mice and hamsters [18,19]; (4) the passive
transfer of autoantibodies from BP patients into CXVII-human-
ized mice induces dermal-epidermal separation [20,21]; (5) the
transfer of maternal antibodies against human BP180/CXVII
induces spontaneous skin blistering in pups humanized for the
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immunized against human BP180/CXVII into Rag2
2/2/
CXVII-humanized mice results in a sustained production of
blister-inducing autoantibodies, partially mimicking the features of
the disease in humans [23]. While the pathogenic role of
autoantibodies to BP230 was suggested by several observations
in patients and experimental animals, the contribution of anti-
BP230 reactivity to disease pathogenesis still needs further
investigation [15,24–26].
Previous attempts to induce blistering by injecting BP patient
IgG into wildtype mice have failed [27,28]. To circumvent this
problem, elegant alternative models have been developed using
the passive transfer of antibodies generated against the murine
autoantigens or, more recently, by the use of patients’
autoantibodies in transgenic mice expressing human BP180/
CXVII [18–21]. These ingenious models reproduce most of the
major disease features and offer unique opportunities to
elucidate the pathomechanisms underlying autoantibody-in-
duced tissue damage in pemphigoid diseases. However, major
shortcomings of these models are: 1) the fact that neonatal mice
injected with BP180/CXVII-specific antibodies do not develop
spontaneous skin blistering and 2) by their experimental design,
the models in neonatal mice have a short observation period and
do not allow for adequately reproducing the course of the
chronic pemphigoid disease for pathogenic and therapeutic
studies.
Therefore, in the present study we set out to develop a
pemphigoid disease model in adult mice reproducing the
spontaneous blistering and the chronic course characteristic of
human condition. In a model of progressive antibody-induced
glomerulonephritis it has been shown that pre-immunization with
rabbit IgG in complete Freund’s adjuvant several days prior to
injection of rabbit anti-mouse glomerular basement membrane
(GBM) antiserum results in strong inflammation with deposition
of IgG and complement C3 and glomerular lesions [29]. Using
this information, we pre-immunized mice with rabbit IgG before
passively transferring rabbit IgG generated against BP180/
CXVII. Mice pre-immunized against rabbit IgG and repeatedly
injected with the BP180/CXVII-specific IgG developed sponta-
neous sustained blistering of the skin. In addition, blistering was
associated with complement activation and recruitment of
inflammatory cells and partly dependent on Ly-6G-positive cells.
In further ex vivo and animal experiments, we investigated the
therapeutic potential of luteolin, a plant flavonoid with potent
anti-inflammatory and anti-oxidative properties [30]. Luteolin
inhibited the Fcc-dependent respiratory burst in immune
complex (IC)-stimulated granulocytes and the autoantibody-
induced dermal-epidermal separation in skin cryosections, but
was not effective in suppressing the skin blistering in the new
animal model of BP.
Results
Generation and characterization of rabbit antibodies
against murine BP180/CXVII
Rabbit antibodies were generated against different fragments of
murine BP180/CXVII by immunizing the animals with a mixture
of the respective recombinant proteins. These antibodies were
shown to bind to the basement membrane zone of murine skin by
indirect immunofluorescence (IF) microscopy (Figure S1A and
B). By immunoblotting, we showed that the generated antibodies
recognized a 180 kDa protein band in extracts of BP180/CXVII-
expressing COS-7 cells (Figure S1C).
Complement-activating capacity of rabbit IgG specific for
murine BP180/CXVII
The complement-activating capacity of BP180/CXVII-specific
IgG was evaluated by an in vitro complement-binding test
(Figure 1). BP180/CXVII-specific IgG (Figure 1A), in contrast
to normal rabbit IgG (Figure 1B), fixed complement at the
epidermal basement membrane.
Granulocyte-activating capacity of rabbit IgG specific for
murine BP180/CXVII
To analyze the ability of ICs composed of rabbit IgG and
murine BP180/CXVII to activate granulocytes, we performed
luminol chemiluminescence assays with granulocytes from healthy
donors (Figure 2A). Incubation of granulocytes with BP180/
CXVII-specific IgG complexed with the antigen, but not with the
antigen alone, resulted in the production of reactive oxygen species
(ROS) (Figure 2A). To assess the capacity of BP180/CXVII-
specific rabbit antibodies to induce granulocyte-dependent der-
mal-epidermal separation in human skin, IgG from pre-immune
rabbits and animals immunized with murine BP180/CXVII was
incubated with skin cryosections, and subsequently with leuko-
cytes. After the addition of leukocytes, BP180/CXVII-specific IgG
induced subepidermal splits in skin cryosections (Figure 2B), in
contrast normal rabbit IgG failed to induce dermal-epidermal
separation in cryosections (Figure 2C).
Pre-immunization of mice against rabbit IgG
To accelerate and increase the inflammatory reaction triggered
by binding of IgG autoantibodies at the DEJ of murine skin, we pre-
immunized mice with purified rabbit IgG mixed with complete
Freund’s adjuvant. Subsequently, mice were injected with BP180/
CXVII-specific or control rabbit IgG. The immunization induced
the production of high levels of mouse IgG against rabbit IgG as
shown by ELISA (Figure S2A). None of the mice pre-immunized
with rabbit IgG showed skin disease clinically and histologically nor
deposition of mouse IgG or complement C3 at the DEJ. However,
injection of mice with BP180/CXVII-specific IgG, but not with
normal rabbit IgG, resulted in deposition of mouse IgG at the
murine epidermal basement membrane as detailed below.
Adult mice injected with BP180/CXVII-specific IgG
develop spontaneous skin blistering
Adult SJL (n=2), BALB/c (n=31), C57BL/6 (n=3) and
C57BL/10 (n=2) mice pre-immunized with rabbit IgG were
Figure 1. Complement-binding capacity of BP180/CXVII-spe-
cific rabbit antibodies. Frozen murine skin sections were incubated
with rabbit antibodies and subsequently with fresh human serum as a
source of complement. Bound C3 was visualized at the dermal-
epidermal junction by fluorochrome-labeled antibody. (A) Deposits of
C3 in sections incubated with BP180/CXVII-specific rabbit antibody. (B)
No C3 deposition in sections incubated with normal rabbit IgG
(magnification, 6400).
doi:10.1371/journal.pone.0031066.g001
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second day with 15 mg of IgG purified from rabbit serum for 12
days. Mice (n=35) injected i.p. (Figure 3) or s.c. (Figure 4) with
IgG from rabbits immunized against murine BP180/CXVII
developed skin lesions, including erythema, blisters and erosions.
In contrast, mice injected with normal rabbit IgG (n=5) did not
show signs of skin disease (Figure 3D–F and 4D). Interestingly,
the blistering phenotype induced by the i.p. injection was different
when compared with the one triggered by the s.c. injection. While
administration of BP180/CXVII-specific IgG by the i.p. route
induced blisters at distant sites, including the ears, paws, eyes and
snouts (Figure 3A–C), the s.c. injections of the BP180/CXVII-
specific IgG resulted in lesions mainly restricted to skin areas in the
proximity of the injection site (Figure 4A–C). Histologically
dermal-epidermal separation of the skin with infiltration of
inflammatory cells is found (Figure 5A–C). Infiltrates were
dominated by neutrophils, with few eosinophils (Figure 5A–B).
The blistering phenotype in mice is associated with
tissue-bound immunoreactants
Direct IF microscopy of perilesional skin revealed linear deposits
of rabbit IgG (Figure 6A) and murine complement C3
(Figure 6B) at the epidermal basement membrane in adult mice
that received IgG specific for BP180/CXVII. In addition,
deposition of murine IgG was found at the basement membrane
in mice injected with BP180/CXVII-specific IgG (Figure 6C),
but not in animals treated with normal rabbit IgG (Figure 6F). In
mice injected with normal rabbit IgG no deposition of IgG
(Figure 6D) and complement C3 (Figure 6E) was detected by IF
microscopy.
Repeated injection of antibodies induces stable
extensive blistering skin disease in mice
In mice injected with rabbit IgG against murine BP180/CXVII,
blistering of the skin started at 3–5 days after the first injection and
developed during the observation period of 19 days to a full-blown
skin blistering disease (Figure 7). The extent of the skin disease was
scored and serum samples were obtained before the first injection of
rabbit IgG (day 0) at day 3 as well as every second day thereafter.
Circulating BP180/CXVII-specific rabbit IgG was detected in
serum samples by ELISA (Figure S2B). During the observation
time, diseaseactivity wasincreasinguntil itreached a plateau around
day 10. Subsequently, while new lesions continued to appear, some
areas re-epithelized showing alopecia without scarring.
Figure 2. Ex vivo granulocyte-activation capacity of BP180/CXVII-specific rabbit IgG antibodies. (A) Leukocytes (3610
7/ml) were
stimulated with rabbit ICs consisting of 5 mg recombinant BP180/CXVII/well and 100 ml of 50-fold diluted BP180/CXVII-specific rabbit serum. ROS
production was measured over a period of 60 min. Data are represented as mean 6 SD; p,0.001. (B, C) Frozen skin sections were incubated with IgG
and with 3610
7 leukocytes/ml. Dermal-epidermal separation was observed in sections treated with (B) BP180/CXVII-specific IgG, but not with (C)
normal rabbit IgG (magnification, 6400).
doi:10.1371/journal.pone.0031066.g002
Figure 3. Intraperitoneal injection of BP180/CXVII-specific IgG induces blister formation in adult mice. Skin lesions, including blisters,
erosions, and crusts developed on the (A) ear, (B) front leg and (C) periocular area in a BALB/c mouse pre-sensitized with rabbit IgG and subsequently
receiving, over a period of 10 days, 6 i.p. injections of IgG, each containing 15 mg of IgG, from a rabbit immunized against murine BP180/CXVII. (D, E,
F) A control mouse pre-sensitized with rabbit IgG and challenged with the same dose of normal rabbit IgG showed no skin alterations.
doi:10.1371/journal.pone.0031066.g003
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in vivo
Since inflammatory infiltrates in our model were mostly
composed of neutrophils, we supposed that these cells mediate
tissue damage. Therefore, to deplete neutrophils we have used a
Ly-6G-specific monoclonal antibody, which induced a severe
reduction of neutrophils from around 30% prior to depletion to
less than 6% of leukocytes in the peripheral blood. The depletion
was maintained for 4 days with a subsequent increase of
Figure 4. Subcutaneous injection of BP180/CXVII-specific IgG
induces blister formation in adult mice. Skin lesions, including
blisters, erosions crusts, and alopecia developed in (A) BALB/c, (B)
C57BL6, and (C) SJL-1 mice pre-sensitized with rabbit IgG and
subsequently receiving, over a period of 10 days, 6 s.c. injections of
IgG, each containing 15 mg of IgG, from a rabbit immunized against
murine BP180/CXVII. (D) A control mouse pre-sensitized with rabbit IgG
and challenged with the same dose of normal rabbit IgG showed no
skin alterations.
doi:10.1371/journal.pone.0031066.g004
Figure 5. Dermal-epidermal separation in mice injected with
BP180/CXVII-specific antibodies. Skin biopsies from mice pre-
sensitized with rabbit IgG and subsequently injected with rabbit IgG
were stained with hematoxylin and eosin. (A) Dense inflammatory
infiltrates dominated by granulocytes in a BALB/c mouse receiving
BP180/CXVII-specific IgG; (B) Subepidermal split and dense inflamma-
tory infiltrates dominated by granulocytes; (C) Extensive dermal-
epidermal separation; (D) Normal histological appearance in a control
mouse receiving normal rabbit IgG (magnification, 6400).
doi:10.1371/journal.pone.0031066.g005
Figure 6. IgG and complement C3 deposition at the basement
membrane in experimental bullous pemphigoid. IF microscopy,
performed on frozen sections of a perilesional mouse skin biopsy
reveals linear deposition of (A) rabbit IgG, (B) murine C3, and (C)
murine IgG at the epidermal basement membrane in a diseased mouse.
No deposits of (D) rabbit IgG, (E) murine C3, and (F) murine IgG of a
control mouse showing no skin lesions (magnification, 6400).
doi:10.1371/journal.pone.0031066.g006
Figure 7. Repeated injections of antibodies against murine
BP180/CXVII induce extensive skin blistering. The extent of
disease was scored as described in Methods. Means of individual clinical
scores of mice injected with BP180/CXVII-specific antibodies (n=9) and
mice injected with normal rabbit IgG (n=5) are shown before the first
injection as well as every subsequent second day for 19 days. The lower
panel shows BALB/c mice at day 12 after the first i.p. injection.
doi:10.1371/journal.pone.0031066.g007
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day. Mice pre-immunized with rabbit IgG and injected with rabbit
IgG specific for BP180/CXVII developed skin blisters (Figure 8A
and B). The transient depletion of neutrophils significantly
reduced the skin blistering disease in the group of mice treated
with the LyG6-specific compared with group treated with the
mock antibody (n=5/group; Figure 8C).
Luteolin inhibits IC-induced ROS production by
leukocytes
Luteolin, a plant-derived flavonoid with potent anti-oxidative
and anti-inflammatory properties, is a promising, small molecule
for the treatment in several inflammatory diseases both by systemic
and local application [30]. Therefore, we have addressed the
effects of luteolin on the autoantibody-induced granulocyte
activation and tissue damage in our model. Human leukocytes
were stimulated with ICs consisting of BP180/CXVII-specific
antibodies and antigen and treated with different concentrations of
luteolin (50–200 mg/ml). Under these conditions, we have
observed an inhibition of ROS production in a dose-dependent
manner (Figure 9A). ROS production may play an important
role in the secretion of gelatinase B (MMP-9) from activated
neutrophils and is believed to be involved in tissue damage in BP.
Therefore, we have asked whether luteolin also inhibits the release
of MMP-9 from leukocytes stimulated with ICs. We show that the
in vitro stimulation of human leukocytes for 3 h with ICs and
different concentrations of luteolin does not inhibit the production
and activation of MMP-9 in the supernatant of these cultures as
detected and quantified by gelatine zymography (Figure 9B).
Luteolin inhibits partly autoantibody-induced
granulocyte-dependent dermal-epidermal separation
ex vivo
We have investigated the effects of luteolin on tissue damage
using an ex vivo cryosection model of autoantibody-induced
granulocyte-dependent dermal-epidermal separation. Cryosec-
tions were treated either with sera from BP patients and BP180/
CXVII-specific rabbit serum or with control sera from healthy
donors and pre-immune rabbits followed by incubation with
granulocytes from healthy donors. Addition of luteolin, but not
vehicle alone, resulted in a significant reduction of the autoanti-
body-induced dermal-epidermal separation (Figure 9C).
Systemic and local application of luteolin does not
significantly impact antibody-induced blistering in vivo
Based on the promising ex vivo results, we have extended the
investigation of the luteolin effects on the autoimmune injury in
our mouse model of BP. We pre-sensitized BALB/c mice with
rabbit IgG and injected them every second day s.c. with BP180/
CXVII-specific IgG or with pre-immune IgG. These mice were
treated every day i.p. either with vehicle alone (n=8) or with 1 mg
of luteolin (n=8). Luteolin administration did not significantly
influence the antibody-induced skin blistering. Mice in both
groups showed similar disease scores and antibodies to rabbit IgG
throughout the experiment (Figure 10C and Figure S3). In a
subsequent experiment, we have also evaluated the effects of a
luteolin-rich topical preparation on the blistering induced in the
ears of mice. For this purpose, we have injected s.c. 1.5 mg
BP180/CXVII-specific (n=14) or control IgG (n=3) into the
mouse ears and applied the luteolin-containing RF-40 (n=10)
preparation or vehicle alone (n=7) every day for 4 days
(Figure 10A and B). No significant changes were observed in
mice topically treated with luteolin compared to those receiving
vehicle alone.
Discussion
Pemphigoid diseases are associated with autoantibodies against
BP180/CXVII and BP230. Data from experimental pemphigoid
models suggest that BP180/CXVII-specific autoantibodies induce
subepidermal skin blistering. Current pemphigoid disease models
use neonatal mice injected with antibodies to BP180/CXVII.
However, in these models, skin blistering does not occur
spontaneously and is only induced when mechanical stress is
applied to the skin. In addition, the experimental design using the
neonatal mouse model of BP allows for observation periods of only
up to 3 days. To address these shortcomings, in the present study
we generated a pemphigoid disease model in adult mice pre-
immunized against rabbit IgG, which developed a spontaneous
extensive blistering skin disease upon injection of murine BP180/
CXVII-specific rabbit antibodies and allowed for longer observa-
tion times.
The passive transfer of pemphigoid patients’ autoantibodies into
mice does not result in skin blistering. This is likely due to both a
limited cross-reactivity of human autoantibodies with the murine
autoantigens and to their lower capacity to activate mouse
complement and leukocytes [28,31]. Therefore, alternative models
using the passive transfer of murine BP180/CXVII-specific
antibodies generated in rabbits into neonatal mice or neonatal
Figure 8. Neutrophil depletion partly inhibits skin blistering
induced by BP180/CXVII-specific IgG in mice. Mice pre-immu-
nized with rabbit IgG and injected i.p. with BP180/CXVII-specific rabbit
IgG were treated with (A) a Ly-6G-specific monoclonal or (B) a mock
antibody as described in Materials and Methods (arrows). (C) Disease
activity during the depletion of Ly-6G-positive cells is significantly
reduced in the group of mice treated with Ly-6G-specific antibody
(n=5) compared with the group treated with mock antibody (n=5;
p,0.05). Data are shown as mean 6 SD.
doi:10.1371/journal.pone.0031066.g008
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been devised [18,20,21]. In a separate study, we could show that
purified rabbit IgG antibodies generated against murine BP180/
CXVII transferred into adult mice results indeed in spontaneous
blistering [32]. However, the disease onset was slower and the
overall disease activity lower compared with other models for
autoimmune subepidermal blistering disease [33] and typical
patients with full-blown disease. To further improve the model, in
the present study, we have applied an approach initially devised
for the autoantibody-induced glomerulonephritis [29,34]. This
progressive nephrotoxic serum nephritis in mice is a prototypic
type II hypersensitivity response in the kidney induced by
antibodies directed against the GBM. Pre-sensitization of mice
with rabbit IgG prior to challenge with rabbit nephrotoxic serum
results in IC formation leading to accelerated glomerular injury
and renal dysfunction that resembles aspects of Goodpasture
syndrome in humans [29]. In our pemphigoid model in adult
mice, pre-sensitization with rabbit IgG resulted in accelerated
onset and enhanced activity of the induced pemphigoid disease
most likely due to IC formation of mouse anti-rabbit IgG and the
tissue-bound rabbit anti-BP180/CXVII.
Our results show the induction of spontaneous skin blisters by
the passive transfer of BP180/CXVII-specific IgG. For the
induction of subepidermal skin blistering, we used purified rabbit
IgG antibodies with high reactivity against the epidermal
basement membrane. Similar to autoantibodies from BP patients
[35] or to rabbit antibodies against collagen VII [33], our rabbit
antibodies fixed complement ex vivo as assessed by an in vitro
complement-binding assay, which measures complement activa-
tion by the classical pathway [36]. We also observed complement
C3 deposits in vivo in our model reproducing the immunopatho-
logical finding of C3 deposits in BP patients.
The infiltration of leukocytes, dominated by granulocytes, into
the upper dermis of the lesional skin is a further major pathological
feature of human BP. We have seen constantly inflammatory
infiltrates consisting predominantly of granulocytes in the skin of
our mice. We could also show that in situ-bound and soluble ICs of
rabbit IgG and BP180/CXVII activated granulocytes resulting in
respiratory burst and dermal-epidermal separation ex vivo.
However, while in approximately 50% of BP patients’ eosinophils
represent the major fraction of recruited cells, in our present
model neutrophils were the main cell type observed. Thus similar
to previous in vivo studies [18–21], eosinophil infiltration, an
important histopathological feature of human BP, is not fully
reproduced in our present model and should be addressed in
further studies.
An interesting observation relates to the different clinical
phenotypes induced in mice injected with BP180/CXVII-specific
IgG depending on the administration route. The i.p. injection of
antibodies resulted in generalized skin blistering with predilection
Figure 9. Luteolin inhibits ROS production, but not the release of MMP-9 from IC-stimulated leukocytes. (A) Leukocytes (3610
7/ml)
were pre-incubated with luteolin in different concentrations or vehicle alone and stimulated with rabbit ICs consisting of 5 mg recombinant BP180/
CXVII/well and 100 ml of 50-fold diluted rabbit serum. ROS production was measured over a period of 60 min. Data are represented as mean 6 SD;
p,0.05. (B)3 610
7/ml leukocytes were stimulated with rabbit ICs consisting of 5 mg recombinant BP180/CXVII/well and 100 ml of 50-fold diluted
rabbit serum for 3 h at 37uC. MMP-9 activation was evaluated by zymography in 50-fold diluted supernatants of these cultures of cells stimulated
with BP180/CXVII (lane 1), BP180/CXVII-specific rabbit IgG (lane 2), ICs (lane 3), ICs with 1000, 500 and 200 mg/ml Luteolin (lanes 4, 5, and 6
respectively). (C) Luteolin inhibits dermal-epidermal separation in cryosection assays ex vivo. Frozen murine skin sections were incubated with pre-
immune rabbit serum or BP180/CXVII-specific rabbit serum. Significantly less dermal-epidermal separation was observed in sections treated with
500 mg/ml luteolin compared with those treated with vehicle alone (magnification, 6400).
doi:10.1371/journal.pone.0031066.g009
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the same IgG preparation triggered extensive skin disease mainly
limited to the proximity of the injection area, although a few
lesions at distant sites were also observed. The cause of this
phenomenon is not known, but is not likely related to a lower
systemic availability of pathogenic antibodies, since the levels of
circulating BP180/CXVII-specific IgG in the two groups were
similar. A further unresolved issue is why lesions develop at
predilection sites when the pathogenic IgG is injected intraperi-
toneally. This site-specificity of the autoimmune attack, which
resembles findings in the passive transfer model of epidermolysis
bullosa acquisita [33], may be explained by the obvious exposure
to increased mechanical trauma and/or by particularities of the
vasculature at these sites that were shown to be relevant in
antibody-dependent models of rheumatoid arthritis [37].
Results from a neonatal model of BP and our previous data
from the ex vivo cryosection model of BP showed that granulocyte
activation is a prerequisite for autoantibody-induced dermal-
epidermal separation [16,38]. In our present study, depletion of
neutrophils using a Ly-6G-specific antibody only partly inhibited
skin blistering induced by BP180/CXVII-specific IgG. While a
straightforward explanation for the relatively modest effect of
neutrophil depletion on skin blistering in the adult model of BP is
difficult to give at this time, a combination of factors is likely to
have contributed to this outcome. First, the ex vivo cryosection
model has an obvious limitation due to the fact that the skin
sections are dead tissue containing damaged cells precluding more
active, keratinocyte-dependent mechanisms to be reproduced in
this model. Second, in the neonatal model granulocytes are
needed for inducing the ‘‘epidermal wrinkling’’ sign by rubbing
the mouse skin. It is however, not known how these cells impact
the development of spontaneous blistering reproduced in the new
animal model presented here. Importantly, as recently suggested,
different mechanisms of autoantibody-induced blister formation
may be in place in BP [39,40], which due to the longer observation
time in the new BP model may have become apparent in our
present study.
Luteolin (39,49,5,7-tetrahydroxyflavone), a plant flavonoid with
potent anti-inflammatory and anti-oxidative properties and a good
safety profile is being investigated as new therapy in inflammatory
autoimmune disease and allergy [30]. Therefore, the aim of a
further set of experiments was to investigate the therapeutic
potential of luteolin in exprimental BP. Initial ex vivo experiments
demonstrated that luteolin inhibited the FccR-dependent produc-
tion of ROS by leukocytes and partly the pemphigoid autoanti-
body-induced granulocyte-dependent dermal-epidermal separa-
tion of skin sections. However, mice treated with luteolin i.p. or by
topical application did not show a lower pemphigoid disease
activity upon challenge with blister-inducing rabbit IgG. Taken
together these results suggest that luteolin is not acting on key
pathogenic mechanisms in experimental BP in vivo and therefore
do not qualify this compound for further exploring its therapeutic
potential for the human pemphigoid disease.
In conclusion, this study demonstrates that the passive transfer
of BP180/CXVII-specific IgG antibodies induces spontaneous
blistering in adult mice and recapitulates the main clinical,
histological, and immunopathological features of human pemphi-
goid disease. A further salient feature of this model is the fact that
it allows longer observation times of the diseased mice. Using this
model we could show that granulocytes significantly contribute to
the autoantibody-triggered tissue damage. Promising ex vivo results
using the anti-inflammatory flavonoid luteolin were not validated
as effective systemic or topical therapy in the experimental
pemphigoid model in vivo. These studies establish an animal model
that will be a useful tool for dissecting the cellular and molecular
mechanisms of blister formation in BP. In addition, this
experimental system will facilitate the development of more
effective therapeutic strategies for managing this chronic autoim-
mune disorder.
Materials and Methods
Mice
The animal’s welfare is checked regularly, and the University
Freiburg Medical Center animal facility complies with the national
and international laws and regulations. The experiments were
approved by the Animal Care and Use Committee (Regierung-
spra ¨sidium Freiburg, Germany; no. G-10/14 and G-10/84) and
performed by certified personnel. 6 to 8-week-old BALB/c,
C57BL/6J, C57BL/10 and SJL female mice with a body weight
of approximately 20 g were obtained from Charles River,
Germany. All injections and bleedings were performed on mice
narcotized by inhalation of isoflurane or intraperitoneal adminis-
tration of a mixture of ketamine (100 mg/g) and xylazine (15 mg/g).
Generation of antibodies against murine BP180/CXVII
Polyclonal antibodies were produced by immunizing rabbits
with 200 mg of a mixture containing purified glutathione S-
Figure 10. In vivo luteolin treatment does not significantly
inhibit blistering in adult mice. BALB/c mice were pre-immunized
with rabbit IgG and injected s.c. with BP180/CXVII-specific IgG. Control
mice were pre-sensitized with rabbit IgG and challenged with the same
dose of normal rabbit IgG showed no skin alterations. Topical treatment
of mice with (A) luteolin at concentrations of 5.24 mM/ear did not result
in different outcome compared with (B) animals treated topically with
vehicle alone. (C) Treatment of mice with 1 mg luteolin i.p. daily (n=8)
did not significantly influence disease activity when compared to mice
treated with vehicle alone (n=8, p.0.5). Data are shown as mean 6
SEM.
doi:10.1371/journal.pone.0031066.g010
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mCXVII-EC7 and GST-mCXVII-IC2 in a 2:1:1:1 molar ratio
in complete Freund’s adjuvant. The recombinant fragments
designated GST-mCXVII-EC1, GST-mCXVII-EC3, GST-
mCXVII-EC7 and GST-mCXVII-IC2 contain murine collagen
XVII sequences stretching from amino acid positions 498–580,
856–901, 1030–1134, and 186–475, respectively [31]. These
GST-fusion proteins containing sequences of murine BP180/
CXVII were cloned and purified as previously described [31,41].
Briefly, recombinant GST fusion and His-tagged proteins were
expressed in E. coli TOP10 and XL1-Blue and purified by
gluthatione agarose and metallochelate affinity chromatography,
respectively as described [16,42]. The animals were boosted twice
(at 15-day interval) with the same protein preparation in
incomplete Freund’s adjuvant. Immune sera were obtained at
regular intervals and characterized by IF microscopy on cryosec-
tions of murine skin.
Affinity purification of rabbit IgG
IgG from rabbit serum or Amicon Ultra-15 filter-concentrated
supernatants from hybridoma cells (clone NIMP-R14) was purified
using Protein G Sepharose Fast Flow affinity column chromatog-
raphy (Amersham Biosciences) as described [43]. Briefly, antibod-
ies were eluted with 0.1 M glycine buffer (pH 2.5), neutralized
with 1.5 M Tris-HCl (pH 10), and concentrated under extensive
washing with PBS (pH 7.2) using Amicon Ultra-15 filters
(Millipore). Purified IgG was filter-sterilized (pore size, 0.22 mm;
Millipore) and the protein concentration was measured spectro-
photometrically at 280 nm. Reactivity of IgG fractions was
analyzed by IF microscopy on murine skin.
Passive transfer experiments and clinical scoring of
disease activity
Adult mice were pre-immunized on day 0 with 200 mg of rabbit
IgG and injected starting with day 3 every second day
subcutaneously (s.c.) or intraperitoneally (i.p.) six times with
15 mg of rabbit IgG against murine BP180/CXVII with end-titer
on adult mouse skin of 1:16,000–32,000. Control mice received
15 mg of pre-immune IgG purified from rabbits. For neutrophil
depletion in vivo BALB/c mice were injected i.p. with 0.125 mg of
the depleting rat anti-Ly-6G antibody or control rat IgG starting 3
days after injection of BP180/CXVII-specific rabbit IgG on days
5, 7, 8, 9, 10, and 11. Luteolin 98 MM was obtained from
International Development and Manufacturing (MMD), dissolved
in 1 M NaOH and diluted 1:10 in PBS to produce a stock solution
of 10 mg/ml (pH 8.5). For the luteolin treatment in vivo, BALB/c
mice were injected i.p. with 1 mg of luteolin dissolved in PBS
(pH 8.5) or vehicle alone every day. In mice the LD50 values are
of .180 mg/kg by i.p. injection [44]. For topical therapy, mice
were injected twice s.c. in the ears with 1.5 mg IgG and the
luteolin-rich Reseda luteola l. extract (RF-40) was topically used at
luteolin concentrations of 5.24 mM/site [45]. All skin samples were
examined by IF microscopy for IgG and complement C3
deposition and by light microscopy (H&E staining) for signs of
dermal-epidermal separation and/or inflammatory infiltrates, as
previously described [46,47]. Mice were weighed daily and
examined for their general condition and for evidence of
cutaneous lesions (i.e., erythema, blisters, erosions, and crusts).
Intact blisters or erosions were counted and the extent of skin
disease was scored as follows: 0, no lesions; 1, fewer than 20 lesions
or less than 10% of the skin surface; 2, more than 20 lesions or 10–
20% of the skin surface; 3, 20–40% of the skin surface; 4, 40–60%
of the skin surface; and 5, more than 60% of the skin surface.
To evaluate the correlation of antibody titers with the extent of
disease, sera were obtained from adult mice at different time
points, including before starting the treatment and 2 days after the
last injection. Sera were assayed for antibody titers by ELISA.
Biopsies of lesional and perilesional skin and esophagus were
obtained 2–3 days after the last injection and prepared for
examination by histopathology and IF microscopy.
IF microscopy
Indirect and direct IF microscopy using rabbit or mouse sera
was performed as described previously [33]. Briefly, indirect IF
was carried out on frozen murine skin sections from untreated
mice, which were incubated 1 h with 100-fold diluted rabbit
serum. Direct IF microscopy was performed using frozen skin
sections from treated mice. Bound immunoreactants were
visualized using a 100-fold diluted AlexaFluor 488-conjugated
antibodies specific for rabbit IgG, mouse C3 and mouse IgG (all
Invitrogen). Complement-fixing activity of antibodies to the DEJ
was determined as described [43]. Briefly, sections of normal
mouse skin were incubated 1 h with 1-fold diluted rabbit sera
against BP180/CXVII or control IgG, followed by washing with
PBS (pH 7.2), twice for 10 min. Subsequently, sections were
treated for 1 h with fresh human serum as a source of
complement, diluted 1:5 with Gelatin Veronal Buffer (Sigma). In
situ complement deposition was visualized using a 100-fold diluted
AlexaFluor-488-conjugated antibody specific for human C3
(Invitrogen).
ROS measurement by luminol chemiluminescence
Human leukocytes were isolated from the peripheral blood of
healthy donors. For the experiments conducted with human
leukocytes, we obtained approval from the Ethics Committee of
the Medical Faculty of the University of Freiburg, Germany
(Institutional Board Project no. 407/08). We obtained written
informed consent from the donors whose material was used in the
study, in adherence to the Helsinki Principles. After 3% dextran
sedimentation erythrocytes were lysed using a hypotonic solution of
0.2% NaCl. Leukocytes were washed in DMEM medium without
supplements and resuspended at a final density of 3610
7 cells/ml.
Cell viability was tested with trypan blue; only preparations with a
viability greater than 95% were used. Plate bound murine ICs were
formed using the recombinant fragments of murine collagen XVII
(GST-mCXVII-EC1, -EC3, -EC7 and -IC2) and rabbit sera from
rabbits immunized against BP180/CXVII. Briefly, 96-well microti-
ter plates were coated with 5 mg of equimolar amounts of GST-
mCXVII-fragments in 0.1 M bicarbonate buffer (pH 9.6). The wells
were washed five times with PBS (pH 7.2) containing 0.05% Tween
20, after each step. After blocking for 1 h with PBS-Tween
containing 1% bovine serum albumin (fraction V; Sigma-Aldrich,
Germany), wells were incubated for 2 h with a 50-fold diluted rabbit
sera against mouse BP180/CXVII. ROS production was measured
using luminol-chemiluminescence. Leukocytes were pre-incubated
for 5 min at 37uCw i t h1 5 0mM luminol (Sigma) and, subsequently,
100 ml of cell suspension was added to each well. To study the effects
of luteolin, leukocytes were pre-incubated with luteolin to a final
concentration of 50, 100, 200 mg/ml or with vehicle alone for
10 min.Allprocedureswere performed in thedark.Unlessotherwise
specified the chemiluminescence intensity was recorded continuously
for 1 h. Kinetic measurement of ROS production in leukocytes
stimulated with PMA (500 nM; Sigma) was conducted as control.
MMP-9 activity measurement by gelatine zymography
Human leukocytes were isolated from the peripheral blood of
healthy donors and treated as described for ROS production. For
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activation by IC-stimulated leukocytes, the cells were pre-
incubated with luteolin to a final concentration of 1000, 500
and 200 mg/ml or with vehicle alone in DMEM for 3 h at 37uC.
The supernatant was collected, diluted 1:50 in PBS and sample
buffer without reducing agents was added. All samples were
loaded and separated for 1–2 h on a 8% SDS-PAGE gel
containing 1% gelatine under non-reducing conditions. Subse-
quently, the gel was stained with Coomassie Brillant Blue staining
solution for 1 h, followed by destaining the gel for 2 h as described
[48].
Flow Cytometry
Blood samples were lysed with ACK lysis buffer, Fc-blocked
with anti-mouse CD16/CD32 and then stained for FACS analysis
with anti-mouse Ly-6G-FITC and anti-mouse Gr-1-PE or isotype
controls as described previously [49,50]. Neutrophils were defined
as Gr-1
+ Ly-6G
+ cells. All antibodies were from BD Pharmingen.
FACS analysis was performed with FACS Canto II (Becton
Dickinson).
Cryosection assay
IgG from rabbits or patients was diluted 1:5 in PBS and the
protein concentration was measured using absorbance at
280 nm. Six-micrometer cryosections of murine or human skin
were washed in PBS to remove embedding medium and
incubated with 100 ml of diluted antibody preparations for 2–
3 h at 37uC. Sections were washed twice with PBS and chambers
were prepared as previously described [41]. Human leukocytes
were isolated from the peripheral blood of healthy donors. For
the experiments conducted with human leukocytes, we obtained
approval from the Ethics Committee of the Medical Faculty of
the University of Freiburg, Germany (Institutional Board Project
no. 407/08). We obtained written informed consent from the
donors whose material was used in the study, in adherence to the
Helsinki Principles. After 3% dextran sedimentation erythrocytes
were lysed using a hypotonic solution of 0.2% NaCl. Leukocytes
were washed in DMEM medium without supplements and
resuspended at a final density of 3610
7 cells/ml. Cell viability
was tested with trypan blue; only preparations with a viability
greater than 95% were used. In some experiments, leukocytes
were pre-incubated with luteolin to a final concentration of 1000,
500 or 200 mg/ml or with vehicle alone for 10 min. Leukocyte
suspensions were injected into the chambers and incubated for
3 h at 37uC. Chambers were then disassembled and sections
washed in PBS, air dried, and stained with hematoxylin and
eosin.
Histology
Biopsies of lesional and perilesional skin and esophagus were
fixed in 3.7% buffered formalin. Sections from paraffin-embedded
tissues were stained with H&E.
Immunoblot analysis
For immunoblotting, subconfluent COS-7 cells transformed
with murine full length BP180/CXVII cDNA or NIMP-R14
hybridoma cells were lysed for 30 min on ice in a buffer containing
1% Triton X-100, 0.137 M NaCl, 20 mM Tris/HCl pH 8.0
(pH 8.0), 2 mM EDTA, and 1 mM Na3VO4, 10% glycerol and
1 mM PMSF [33]. The samples were separated by SDS-PAGE on
6% polyacrylamide gels, followed by transfer onto nitrocellulose
membrane. 200-fold diluted polyclonal rabbit antibodies directed
against murine BP180/CXVII as described above were used.
After incubation with a chicken anti-rabbit IgG HRP-conjugated
secondary antibody (Novus biologicals), signals were visualized by
3,39-diaminobenzidine (Merck) [41].
ELISA
ELISA was used to measure circulating mouse IgG against
rabbit IgG following established protocols with minor modification
[51]. Briefly, 500 ng purified normal rabbit IgG were immobilized
on 96-well microtiter plates using 0.1 M bicarbonate buffer
(pH 9.6). After each step, the wells were washed four times with
PBS (pH 7.2) containing 0.05% Tween 20, unless otherwise
specified. After blocking for 1–2 h with PBS-Tween containing
1% bovine serum albumin (fraction V; Sigma-Aldrich), wells were
incubated for 2 h with a 250-fold dilution of mouse sera. Bound
antibodies were detected using a 3,000-fold dilution of an HRP-
labeled goat anti-mouse IgG antibodies (BioRad) and orthophe-
nylene diamine (Dako) as a chromophore (490 nm).
ELISA was used to measure circulating rabbit IgG against
BP180/CXVII following established protocols with minor mod-
ification [51]. Briefly, 300 ng of the purified His-tagged murine
BP180/CXVII (EC1 fragment) was immobilized on 96-well
microtiter plates using 0.1 M bicarbonate buffer (pH 9.6). After
each step, the wells were washed four times with PBS (pH 7.2)
containing 0.05% Tween 20, unless otherwise specified. After
blocking for 2 h with PBS-Tween containing 1% bovine serum
albumin (Sigma-Aldrich), wells were incubated for 2 h with a 100-
fold dilution of mouse sera. Bound antibodies were detected using
a 3,000-fold dilution of a chicken anti-rabbit IgG HRP (NOVUS
biologicals) and orthophenylene diamine (Dako) as a chromophore
(492 nm).
Statistical analysis
All analyzes were performed using GraphPad Prism Version
5.03. Continuous variables were compared using the Man-
Whitney U or Students’ t test. P,0.05 was considered statistically
significant.
Supporting Information
Figure S1 Reactivity and specificity of IgG antibodies
from rabbits immunized with murine BP180/CXVII.
Frozen skin sections were incubated with 100-fold diluted serum
from a rabbit (A) immunized against BP180/CXVII or (B) pre-
immune rabbit serum. (C) Extracts of the NIMP-R14 hybridoma
cell line (lanes 1 and 3) and of BP180/CXVII-expressing COS-7
cells (lanes 2 and 4) were separated by 6% SDS-PAGE and
immunoblottted with 200-fold diluted pre-immune rabbit serum
(lanes 1 and 2) or serum from a rabbit immunized against BP180/
CXVII (lanes 3 and 4).
(TIF)
Figure S2 (A) Serum levels of mouse IgG antibodies against
rabbit IgG. Levels of murine IgG in serum samples of pre-
immunized mice, which were subsequently injected with BP180/
CXVII-specific (n=5) or control (n=3) rabbit IgG were measured
by an ELISA using rabbit IgG as antigen as described in Materials
and Methods. Data are shown as mean 6 SD. (B) Serum levels
of rabbit IgG against BP180/CXVII in mice. Levels of
rabbit IgG autoantibodies in serum samples of mice injected with
BP180/CXVII-specific (n=9) or control (n=5) rabbit IgG were
measured by an ELISA using recombinant BP180/CXVII, as
described in Materials and Methods. Data are shown as mean 6
SD.
(TIF)
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the injected pathogenic BP180/CXVII-specific IgG and
of rabbit IgG-specific mouse IgG antibodies. (A) Serum
levels of mouse IgG antibodies against rabbit IgG. Levels
of murine IgG in serum samples of pre-immunized mice, which
were subsequently injected with BP180/CXVII-specific (n=16) or
control (n=11) rabbit IgG and treated with luteolin (n=14) or
vehicle (n=13) were measured by an ELISA using rabbit IgG as
antigen as described in Materials and Methods. Data are shown as
mean 6 SD. (B) Serum levels of rabbit IgG against BP180/
CXVII in mice. Levels of rabbit IgG autoantibodies in serum
samples of mice injected with BP180/CXVII-specific (n=16) or
control (n=11) rabbit IgG and subsequently treated with luteolin
(n=14) or vehicle (n=13) were measured by an ELISA using
recombinant BP180/CXVII, as described in Materials and
Methods. Data are shown as mean 6 SD.
(TIF)
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